Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05021835 (ZEUS) for Cardiovascular Risk, Chronic Kidney Disease, Inflammation is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation Phase 3 6,200 Pregnancy
Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided b...
Show MoreZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
- ZEUS
- EX6018-4758
- U1111-1259-3422 (Other Identifier) (World Health Organization (WHO))
- 2023-506926-35 (Other Identifier) (European Medical Agency (EMA))
- jRCT2021210033 (Registry Identifier) (JAPIC)
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalZiltivekimab Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years. | Ziltivekimab B Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. Ziltivekimab C Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
Placebo ComparatorPlacebo Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years. | Placebo (Ziltivekimab B) Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. Placebo (Ziltivekimab C) Administered subcutaneously (s.c., under skin) once-monthly added to standard of care. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke | Months | From randomisation (month 0) to end-of-study (up to 48 months) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Time to first occurrence of expanded MACE, a composite endpoint consisting of: CV death, non-fatal MI, non-fatal stroke and hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation | Months | From randomisation (month 0) to end-of-study (up to 48 months) |
Number of heart failure hospitalisations or urgent heart failure visits or CV deaths | Count | From randomisation (month 0) to end-of-study (up to 48 months) |
Time to first occurrence of a composite kidney endpoint consisting of: CV death, onset of persistent atleast 40 percent (%) reduction in eGFR (CKD-epidemiology collaboration [CKD-EPI]) compared with baseline, kidney failure | Months | From randomisation (month 0) to end-of-study (up to 48 months) |
Time to occurrence of all-cause mortality | Months | From randomisation (month 0) to end-of-study (up to 48 months) |
Time to first occurrence of each of the individual components of the expanded MACE endpoint and the kidney composite endpoint. | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Time to first occurrence of MI (fatal and non-fatal). | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Time to first occurrence of stroke (fatal and non-fatal). | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Time to first occurrence of a composite MACE endpoint consisting of: all-cause mortality, non-fatal MI and non-fatal stroke | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Time to first occurrence of a 4-component kidney endpoint consisting of: onset of persistent at least 40% reduction in eGFR (CKD-EPI) compared with baseline, kidney failure | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Time to first occurrence of coronary revascularisation | Months | From randomisation (month 0) to end-of-study (up to 48 months). |
Change in Urinary Abumin-to-Ceatinine ratio (UACR). | Percentage | From randomisation (month 0) to 2 years (24 months). |
Change in eGFR (CKD-EPI)) | mL/min/1.73 m\^2 | From randomisation (month 0) to 2 years (24 months) |
Annual rate of change in eGFR (CKD-EPI) (total eGFR slope) | mL/min/1.73 m\^2/ year | From randomisation (month 0) to end-of-study (up to 48 months). |
Change in high-sensitivity C-reactive protein (hs-CRP) | Percentage | From randomisation (month 0) to 2 years (24 months |
Change in N-terminal-pro-brain natriuretic peptide ( NT-pro-BNP) | Percentage | From randomisation (month 0) to 2 years (24 months) |
Change in left ventricular ejection fraction (LVEF) | Percentage | From randomisation (month 0) to 2 years (24 months) |
Number of events of atrial fibrillation | Count | From randomisation (month 0) to end-of-study (up to 48 months). |
Change in haemoglobin | Grams per deciliter (g/dL) | From randomisation (month 0) to 2 years (24 months) |
Number of hospitalisations with infection as primary cause or death due to infection. | Count | From randomisation (month 0) to end-of-study (up to 48 months). |
Change in Short Form 36 (SF-36) Physical Component Score (PCS) | Score on scale | From randomisation (month 0) to 2 years (24 months) |
Chronic kidney disease defined by one of the below:
- Estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 15 and below 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
- Urinary albumin-to-creatinine ratio (UACR) >= 200 milligrams per gram (mg/g) and eGFR >= 60 mL/min/1.73 m2 (using the CKD-EPI creatinine equation)
Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligram per liter (mg/L)
Evidence of atherosclerotic cardiovascular disease (ASCVD) by one or more of the following:
a) Coronary heart disease defined as at least one of the following: i. Documented history of MI ii. Prior coronary revascularisation procedure iii. greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke of atherosclerotic origin ii. Prior carotid artery revascularisation procedure iii. greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularisation procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
- Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days prior to randomisation (visit 2).
- Planned coronary, carotid or peripheral artery revascularisation known on the day of randomisation (visit 2).
- Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
Cheshire
Dorset
Lancashire
North Yorkshire
Northamptonshire
Surrey
West Sussex
Stockholm County
Region Sjælland
Baden-Wurttemberg
Holstein
Thuringia
Eastern Cape
Free State
Gauteng
KwaZulu-Natal
Western Cape
City of Zagreb
Krapinsko Zagorska County
Attica
Bucharest
Bucurestii
Cluj
Bekes County
Komárom-Esztergom
Zala County
Vojvodina
Alabama
Arizona
Arkansas
California
Colorado
Connecticut
District of Columbia
Florida
Georgia
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Maryland
Massachusetts
Michigan
Minnesota
Missouri
Nebraska
Nevada
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Pennsylvania
Rhode Island
South Carolina
Tennessee
Texas
Utah
Virginia
Washington
Wisconsin
Buenos Aires
Australian Capital Territory
New South Wales
Queensland
South Australia
Tasmania
Victoria
Western Australia
Espírito Santo
Federal District
Minas Gerais
Paraná
Santa Catarina
São Paulo
Alberta
British Columbia
Nova Scotia
Ontario
Quebec
Anhui
Beijing Municipality
Chongqing Municipality
Fujian
Gansu
Guangdong
Guangxi
Hainan
Hebei
Henan
Hubei
Hunan
Jiangsu
Jiangxi
Jilin
Liaoning
Shaanxi
Shandong
Shanghai Municipality
Shanxi
Sichuan
Tianjin Municipality
Yunnan
Zhejiang
Andhra Pradesh
Gujarat
Karnataka
Karnatka
Kerala
Maharashtra
National Capital Territory of Delhi
New Delhi
Punjab
Tamil Nadu
Telangana
Uttar Pradesh
Cz
Fe
Lombardy
RM
Ehime
Fukushima, Japan
Kumamoto, Japan
Miyazaki
Kedah
Kelantan
Kuala Lumpur
Perak
Sarawak
Selangor
Estado de Baja California
Jalisco
Mexico City
México, D.F.
Nuevo León
San Luis Potosí
Sinaloa
Kuyavian-Pomeranian Voivodeship
Lesser Poland Voivodeship
Lower Silesian Voivodeship
Lublin Voivodeship
Lubusz Voivodeship
Podlaskie Voivodeship
Pomeranian Voivodeship
Silesian Voivodeship
Łódź Voivodeship
Lisbon District
Matosinhos
Madrid
Murcia
Bangkok
Changwat Pathum Thani
Changwat Songkhla
Mueang Chiang Mai
Patumwan
Rajathewee
Thung Phayathai Subdistrict
Bakirkoy